Coherus Oncology Inc (CHRS) trimmed headcount by 30% and lowered its breakeven threshold while revising 2026 Loqtorzi guidance to $54-$57 million amid a sub-12-month cash runway.
2026-11-02. The following slide deck was published by Coherus Oncology, Inc.
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 10, 2026, at 7:30 a.m. Eastern Daylight Time.Jefferies Global Healthcare Conference in London, UK on Monday, November 16, 2026, at 10:30 a.m. Greenwich Mountain Time / 5:30 a.m. Eastern Daylight Ti
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion le
Coherus Oncology (CHRS) said Wednesday it has begun the process to sell remaining assets related to
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.Morgan Stanley 24th Annual Global Healthcare Confere
This is the newest page. Registered accounts read further back.